Cellectis S.A. Files $115M IPO

Cellectis S.A. (Nasdaq: CLLS) filed a registraiton with the U.S. SEC for an IPO of its American Depository Shares (ADSs). The proposed maximum offering price is $115 million. The company plans to list on the Nasdaq under the ticker, CLLS.

The offering is being made via BofA Merrill Lynch, Jefferies, Piper Jaffray, Oppenheimer & Co., and Trout Capital.

Revenue for the six-month period enters June 30, 2014, was €10.28 million with net loss of €0.34 per share, compared with revenue of €5.19 million and loss of €0.81 per share reported for the first-half of 2013. H114 revs were $14.1 million for loss of $0.47 per share.

Cellectis is a gene-editing company, which employs its core proprietary technologies to develop best-in-class products in the emerging field of immuno-oncology.

You May Also Be Interested In

• APi Group Corporation (APG) Prices 11M Share Offering at $37.50/sh
• Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
• Korro Bio (KRRO) Announces $70M Placement